AI Article Synopsis

  • Ureteral reimplantation for infants with primary obstructive megaureter (POM) is difficult, and the study investigates whether high pressure balloon dilation (HPBD) can be an effective treatment or a temporary solution.
  • The study reviewed patients under one year of age who underwent HPBD, excluding those with certain conditions or prior surgeries, and focused on outcomes like megaureter resolution and reimplantation rates.
  • Results showed that 80% of infants benefited from HPBD, with significant improvement in ureter size and hydronephrosis, while 20% required further surgery due to persistent issues.

Article Abstract

Introduction And Objective: Ureteral reimplantation of the dilated ureter in infants is challenging; however, some patients with primary obstructive megaureter (POM) in this age group require intervention due to clinical or radiological progression. We sought to determine if high pressure balloon dilation (HPBD) can serve as a definitive treatment for POM in children under one year of age, or as a temporizing measure until later reimplantation.

Materials And Methods: All patients from a single institution who underwent HPBD between October 2009 and May 2022 were retrospectively reviewed. Patients were excluded if older than 12 months or diagnosed with neurogenic bladder, posterior urethral valves, or obstructed refluxing megaureter. Patients with prior surgical intervention at the ureterovesical junction were excluded. Indications for surgery included progressive hydroureteronephrosis or urinary tract infection (UTI). Balloon dilation was performed via cystoscopy with fluoroscopic guidance, followed by placement of two temporary ureteral stents. Primary outcomes were improvement or resolution of megaureter and rates of subsequent reimplantation. Secondary outcomes included total number of anesthetics and postoperative UTIs.

Results: Fifteen infants with median age of 7.6 months (IQR 3.8-9.7) underwent HPBD. Twelve (80%) patients were detected prenatally and 3 (20%) after a UTI. Indication for surgery was progressive hydroureteronephrosis in 10 patients (67%) and UTI in five (33%). All had SFU grade 3 or 4 hydronephrosis on preoperative ultrasound and median distal ureteral diameter was 13 mm. Median follow up was 2.9 years. Twelve (80%) succeeded with endoscopic treatment: 7 patients had an undetectable distal ureter on ultrasound at last follow-up, 5 were improved with median distal ureteral diameter of 7 mm. Three patients (20%) required ureteral reimplantation due to progressive dilation, all with grade 4 hydronephrosis and distal ureteral diameters were 11, 15, and 21 mm. Six patients (40%) required two anesthetics to complete endoscopic treatment. Among those, 4 patients required initial stent placement for passive dilation followed by a second anesthetic for HPBD weeks later. Two patients underwent repeat HPBD following postoperative proximal migration of the ureteral stents. All 15 patients had an additional anesthetic for removal of stents. Five patients (33%) were treated for a symptomatic UTI (4 febrile, 1 afebrile) with the stents indwelling but there were no UTIs in the group following stent removal.

Conclusion: Balloon dilation is a practical option for treatment of POM in infants, and in most cases (80%) avoids subsequent open surgery (over median 2.9 years of follow-up).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpurol.2023.09.007DOI Listing

Publication Analysis

Top Keywords

balloon dilation
16
patients
13
endoscopic treatment
12
distal ureteral
12
primary obstructive
8
obstructive megaureter
8
high pressure
8
pressure balloon
8
ureteral reimplantation
8
treatment pom
8

Similar Publications

Aim: To investigate the clinical efficacy of transurethral columnar balloon dilation of prostate (TUCBDP) in the treatment of small-volume benign prostatic hyperplasia (BPH) and provide the optimal treatment for the surgical treatment of small volume benign prostatic hyperplasia.

Methods: This retrospective study analyzed 106 patients with small-volume BPH who underwent surgical treatment at the Department of Urology, Xiangya Changde Hospital from December 2023 to January 2024. The patients were divided into two groups based on the type of surgery received: TUCBDP group (n = 53) and transurethral resection of prostate (TURP) group (n = 53), which serves as the control group.

View Article and Find Full Text PDF

Background: Endovascular recanalization with venous stenting is the preferred treatment for iliofemoral venous obstruction. We reviewed our institutional experience and mid-term outcomes with endovascular therapy for iliofemoral venous obstruction using the Venovo Self-expanding Venous Stent (BARD Peripheral Vascular, Inc., Tempe, AZ, USA).

View Article and Find Full Text PDF

Effectiveness of the repeated 3-time-balloon-inflation method in reducing coronary stent edge dissection.

Heart Vessels

December 2024

Division of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, 86 Nishicho, Yonago, Japan.

The optimal procedural protocol for coronary stent deployment remains undetermined. Post-dilation with a high-pressure balloon is often performed to optimize the stent expansion. However, high-pressure dilation also carries the potential risk of coronary artery injury.

View Article and Find Full Text PDF

Background & Aims: The effectiveness of endoscopic papillary large balloon dilation (EPLBD) alone versus EPLBD combined with endoscopic sphincterotomy (EST) in treating large common bile duct stones (CBDS, ≥ 15 mm) remains unclear. This study aimed to evaluate the safety and treatment outcomes of EPLBD combined with limited or large EST versus EPLBD alone in removing large CBDS.

Methods: Between January 2013 and September 2024, 408 patients underwent EPLBD, either alone or in combination with EST, to treat large CBDS (≥ 15 mm).

View Article and Find Full Text PDF

The Optilume drug-coated balloon (DCB) (North Plymouth, USA) is a novel treatment option for urethral stricture disease that combines mechanical dilation with localized delivery of paclitaxel, an antiproliferative drug aimed at reducing recurrence rates by inhibiting scar tissue formation. This systematic review and meta-analysis, conducted using studies published in the last 10 years up to November 2024, assessed the efficacy and safety of Optilume DCB across seven studies involving 457 patients. Key outcomes included significant reductions in symptom scores, as measured by the International Prostate Symptom Score (IPSS), and improvements in urinary flow rates (QMax).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!